Drug Development Pipeline for Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2 (DM2)
Below is a pipeline of potential therapies being developed by pharmaceutical companies. Please note that any work being conducted solely by universities has not been included in this table, as any therapy that is going to be licensed requires the involvement of a company. The table includes therapies in early laboratory development all the way up to early and late clinical development.
View as PDF file (opens in new window and zoom in for the highest quality)
This information is accurate as of 01/07/19. This was initially based on the work of Nate Uhl at www.myotonicpipeline.com. Nate can be contacted at firstname.lastname@example.org or on his twitter page: @DM1research
If you have any questions do not hesitate to contact the registry curator at: email@example.com